Keith Booher
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$6.8MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $6.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 11, 2026 | NIH | STTR Phase II A Novel Xenon Delivery Platform for Cerebroprotection During Stroke | $908K | ZYMO RESEARCH CORP. |
| Aug 6, 2025 | NIH | STTR Phase II A Novel Xenon Delivery Platform for Cerebroprotection During Stroke | $981K | ZYMO RESEARCH CORP. |
| Aug 26, 2024 | NIH | STTR Phase II A Novel Xenon Delivery Platform for Cerebroprotection During Stroke | $632K | ZYMO RESEARCH CORP. |
| Dec 29, 2021 | NIH | STTR Phase II Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment | $841K | ZYMO RESEARCH CORP. |
| 2021 | NIH | STTR Phase II Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment | $1.9M | ZYMO RESEARCH CORP. with UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON |
| Dec 28, 2020 | NIH | STTR Phase II Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment | $1.1M | ZYMO RESEARCH CORP. |
| May 1, 2017 | NIH | STTR Phase I Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment | $225K | ZYMO RESEARCH CORP. with UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON |
| Apr 27, 2017 | NIH | STTR Phase I Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment | $225K | ZYMO RESEARCH CORP. |
Peer ranks
Federal funding#157
Awards as PI#216
Patents#505
Companies
- ZYMO RESEARCH CORP.Linked by awards · Medtech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.